Table 1. Demographics and medical treatment in the two MDS patients.

	Sex (M/F)	Age at surgery (years)	Age at onset (yeas)	DYT1	DYT11	Predominant complaints on admission	Myoclonus distribution	Dystonia distribution	Alcohol sensitivity	DBS	Previous medical treatment	Follow up (months)
P1	M	30	12	c.904_906delGAG, p.Glu303del(exon5)	c.1294 A > C, p.Ser432Arg (exon10)	myoclonus	neck, trunk, UL, LL	voice, neck, trunk, UL, LL	+	Vim, GPi*	trihexyphenidyl, selegiline, clonazepam	54
P2	M	17	11	c.904_906delGAG, p.Glu303del(exon5)	c.1294 A > C, p.Ser432Arg (exon10)	hand dystonia	UL, LL	voice, UL, LL	Not test	Vim	clonazepam	6

MDS: myoclonus dystonia syndrome, M/F: Male/Female, DYT1: Torsin A gene mutation, DYT11: SGCE gene mutation, +: positive, −: negative, GPi: globus pallidus internus, Vim: ventral intermediate thalamic nucleus, UL: upper limb, LL: lower limb. *Initial bilateral Vim DBS was performed and subsequent bilateral GPi DBS was offered at 43 months after initial surgery.